168 related articles for article (PubMed ID: 1813288)
21. The efficacy and safety of recombinant tissue plasminogen activator infusion in acute myocardial infarction.
Wang SP; Liu CP; Charng MJ; Chou CY; Tsai JH; Pan JP; Shyong WC; Chan WL; Kong CW; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 1989 Apr; 43(4):223-8. PubMed ID: 2509051
[TBL] [Abstract][Full Text] [Related]
22. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
Malcolm AD; Keltai M; Walsh MJ
Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
[TBL] [Abstract][Full Text] [Related]
23. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
[TBL] [Abstract][Full Text] [Related]
24. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
TIMI Study Group
N Engl J Med; 1989 Mar; 320(10):618-27. PubMed ID: 2563896
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction.
Khan MI; Hackett DR; Andreotti F; Davies GJ; Regan T; Haider AW; McFadden E; Halson P; Maseri A
Am J Cardiol; 1990 May; 65(16):1051-6. PubMed ID: 2109926
[TBL] [Abstract][Full Text] [Related]
26. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
Miyazaki A; Tadokoro H; Drury JK; Rydén L; Haendchen RV; Corday E
J Am Coll Cardiol; 1991 Aug; 18(2):613-20. PubMed ID: 1906906
[TBL] [Abstract][Full Text] [Related]
27. Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction.
Tranchesi B; Chamone DF; Cobbaert C; Van de Werf F; Vanhove P; Verstraete M
Am J Cardiol; 1991 Jul; 68(2):161-5. PubMed ID: 1829574
[TBL] [Abstract][Full Text] [Related]
28. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.
Tebbe U; Tanswell P; Seifried E; Feuerer W; Scholz KH; Herrmann KS
Am J Cardiol; 1989 Sep; 64(8):448-53. PubMed ID: 2505604
[TBL] [Abstract][Full Text] [Related]
29. Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan.
Kanemoto N; Goto Y; Hirosawa K; Kawai C; Kimata S; Yui Y; Yamamoto Y
Jpn Circ J; 1991 Mar; 55(3):250-61. PubMed ID: 1903167
[TBL] [Abstract][Full Text] [Related]
30. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
Van de Werf F; Arnold AE
BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
[TBL] [Abstract][Full Text] [Related]
31. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
DeWood MA; Kurnik PB; Jolly MK; Jain AC; Khaja F; Gorfinkel HJ; Morris DL; Satler L; LittleJohn J
Clin Cardiol; 1993 Apr; 16(4):302-10. PubMed ID: 8458110
[TBL] [Abstract][Full Text] [Related]
32. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction.
Tebbe U; von Essen R; Smolarz A; Limbourg P; Rox J; Rustige J; Vogt A; Wagner J; Meyer-Sabellek W; Neuhaus KL
Am J Cardiol; 1993 Sep; 72(7):518-24. PubMed ID: 8362764
[TBL] [Abstract][Full Text] [Related]
33. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
Bleich SD; Nichols TC; Schumacher RR; Cooke DH; Tate DA; Teichman SL
Am J Cardiol; 1990 Dec; 66(20):1412-7. PubMed ID: 2123602
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
Hackett D; Andreotti F; Haider AW; Brunelli C; Shahi M; Fussell A; Buller N; Foale R; Lipkin D; Caponnetto S
Am J Cardiol; 1992 Jun; 69(17):1393-8. PubMed ID: 1590225
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of a new regimen of intravenous recombinant tissue-type plasminogen activator potentially suitable for either prehospital or in-hospital administration.
McKendall GR; Attubato MJ; Drew TM; Feit F; Sharaf BL; Thomas ES; Teichman S; McDonald MJ; Williams DO
J Am Coll Cardiol; 1991 Dec; 18(7):1774-8. PubMed ID: 1960329
[TBL] [Abstract][Full Text] [Related]
36. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Thompson PL; Aylward PE; Federman J; Giles RW; Harris PJ; Hodge RL; Nelson GI; Thomson A; Tonkin AM; Walsh WF
Circulation; 1991 May; 83(5):1534-42. PubMed ID: 1902404
[TBL] [Abstract][Full Text] [Related]
37. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.
Verstraete M; Arnold AE; Brower RW; Collen D; de Bono DP; De Zwaan C; Erbel R; Hillis WS; Lennane RJ; Lubsen J
Am J Cardiol; 1987 Aug; 60(4):231-7. PubMed ID: 3113222
[TBL] [Abstract][Full Text] [Related]
38. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
de Bono DP
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717
[TBL] [Abstract][Full Text] [Related]
39. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators.
Carney RJ; Murphy GA; Brandt TR; Daley PJ; Pickering E; White HJ; McDonough TJ; Vermilya SK; Teichman SL
J Am Coll Cardiol; 1992 Jul; 20(1):17-23. PubMed ID: 1607520
[TBL] [Abstract][Full Text] [Related]
40. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial.
Dalen JE; Gore JM; Braunwald E; Borer J; Goldberg RJ; Passamani ER; Forman S; Knatterud G
Am J Cardiol; 1988 Aug; 62(4):179-85. PubMed ID: 3135737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
